Community observations, not medical advice.Always speak with a qualified healthcare professional.

The Longevity Hub

Every longevity drug and intervention people are talking about — sorted by how strong the evidence actually is, with the subscription-based routes people really use to access them in the UK.

Last reviewed: 17 September 2026 · Works for Us research team · Educational, not medical advice

What this is (and isn't)

Longevity has moved from fringe to checkout page. GLP-1s reshaped obesity medicine and proved that a drug can move hard cardiovascular endpoints through weight; subscription supplement companies sell "cellular repair" on a monthly direct debit; private clinics bundle diagnostics and off-label prescriptions into membership tiers. The money is arriving faster than the evidence.

Works for Us exists because the only honest answer to "what actually works?" is evidence tiers, not enthusiasm. So that's how this page is built. Every named drug below sits in exactly one tier, with its caveat stated plainly. We don't sell medicines, we don't take supplement-company money, and every prescription-only molecule named here is one a clinician — not a website — decides on. See our FAQ and how the platform works.

How to read these tiers

The organising logic is the strength of human evidence, because that's what separates the compounds worth your attention from the compounds worth somebody's revenue:

Tier ARandomised trials or outcome data in humans for a relevant endpoint.
Tier BMechanistic plus limited human data — biomarkers move, endpoints unproven.
Tier CAnimal, preclinical, or pipeline. Interesting biology; nothing you should buy on.

Tier A — Strong human evidence

Large randomised trials or outcome data in humans for a relevant endpoint. These are prescription-only medicines (POM). Works for Us does not sell them, and nothing here is medical advice — they are prescribed by clinicians for approved indications, with longevity-adjacent benefits emerging from outcome trials.

GLP-1 receptor agonists (semaglutide, tirzepatide)

The obesity-to-cardiovascular-outcome story

Evidence: The SELECT trial (17,604 adults with established cardiovascular disease and obesity, no diabetes) found semaglutide reduced major adverse cardiovascular events by 20% over ~3 years (NEJM 2023). SURMOUNT-1 showed tirzepatide produced ~21% mean weight loss at the top dose over 72 weeks (NEJM 2022). For the first time, a drug class moved the needle on hard cardiovascular endpoints through weight management — the closest thing longevity medicine has to a proven lever.

Caveats: Muscle-mass loss alongside fat loss, GI side effects, and lifelong-in-principle dosing economics are unresolved questions. Licensed in the UK for obesity and diabetes under clinician supervision — not a casual purchase, and not licensed as a 'longevity drug'.

Browse compound data→ compound index (no page yet)

Named a prescription medicine? Decisions on starting, stopping, or combining belong with a qualified clinician.

Metformin

The cheapest longevity candidate ever tested

Evidence: Decades of diabetes-outcome data, including the UKPDS 'legacy effect' (cardiovascular benefit persisting years after the trial ended). The Targeting Aging with Metformin (TAME) trial — FDA-endorsed, AFAR-coordinated — is the first trial designed to test a drug against aging as an endpoint in ~3,000 older adults.

Caveats: TAME results are not in. Outside diabetes, human evidence for metformin as a longevity intervention is observational and thin; some athlete studies even hint at blunted exercise adaptations. Prescription-only in the UK.

Browse compound data→ compound index (no page yet)

Named a prescription medicine? Decisions on starting, stopping, or combining belong with a qualified clinician.

Tier B — Promising, limited human evidence

Real biological signals — mostly mechanistic, biomarker, or animal data — without large human endpoint trials. Access ranges from prescription to supplement counter; quality of evidence and of products varies accordingly.

Rapamycin / sirolimus (mTOR inhibition)

The most consistent life-extension drug in mice

Evidence: The NIA Intervention Testing Program (ITP) repeatedly extended lifespan in genetically heterogeneous mice with rapamycin started even late in life (Miller et al., Aging Cell 2014 and follow-ups) — one of the most replicated mouse findings in geroscience.

Caveats: Human longevity data: none. Chronic dosing carries immune suppression, lipid, and wound-healing risks (it is a transplant immunosuppressant). Off-label 'longevity dosing' exists in private clinics; that is a clinician conversation with real trade-offs, not a supplement decision.

Browse compound data→ compound index (no page yet)

Named a prescription medicine? Decisions on starting, stopping, or combining belong with a qualified clinician.

NAD+ precursors (NR, NMN)

The subscription-supplement poster child

Evidence: Small human trials show NAD+ levels in blood rise reliably (e.g. Martens et al. 2018, which also saw a blood-pressure trend). Mechanistic work on sirtuins and mitochondrial function is extensive.

Caveats: No human trial has shown a clinical endpoint — survival, disease, function — improving. NMN's regulatory status is contested (novel-food battles in the US/UK). This category is sold on mechanism, not outcomes.

Browse compound data→ compound index (no page yet)

Named a prescription medicine? Decisions on starting, stopping, or combining belong with a qualified clinician.

Taurine

A real signal, in mice and monkeys

Evidence: Singh et al. (Science 2023) found taurine supplementation improved healthspan markers and lifespan in mice and monkeys, with taurine levels declining with age across species — a genuinely interesting paper.

Caveats: No human endpoint evidence; the ageing effect has not been demonstrated in people. Human data is limited to small blood-pressure and exercise-metabolism trials. Well tolerated up to 3 g/day per EFSA.

Taurine: see what users report→ compound page

Named a prescription medicine? Decisions on starting, stopping, or combining belong with a qualified clinician.

Omega-3 (EPA/DHA)

The old reliable — with a split verdict

Evidence: REDUCE-IT (icosapent ethyl, prescription EPA) reduced cardiovascular events in high-risk patients on statins. Blood-pressure and triglyceride effects are real and measurable.

Caveats: General-population supplement trials (VITAL, ASCEND) found no reduction in cardiovascular events, and meta-analyses show no all-cause mortality benefit; high doses carry an atrial-fibrillation signal. Food-first still wins for most people.

Omega-3: see what users report→ compound page

Named a prescription medicine? Decisions on starting, stopping, or combining belong with a qualified clinician.

Tier C — Speculative, animal, or horizon

Fascinating biology that has not yet produced human evidence — or is not buyable at all yet. Named here because you will hear about them; understanding what tier they sit in is the whole point of this page.

Senolytics (fisetin, dasatinib + quercetin)

Clearing 'zombie' cells

Evidence: Compelling senescent-cell biology; small human trials of dasatinib + quercetin (e.g. Hickson et al. 2019) showed modulate-able senescence markers. Fisetin was tested by the ITP.

Caveats: The ITP's fisetin arms did not extend mouse lifespan — a caution against supplement-aisle senolytic claims. No human endpoint data for any senolytic.

Browse compound data→ compound index (no page yet)

Named a prescription medicine? Decisions on starting, stopping, or combining belong with a qualified clinician.

Naproxen

The mouse data everyone misquotes

Evidence: ITP 2024: naproxen extended median lifespan ~14% — in male mice only (Aging Biology). That is a genuinely striking result in geroscience.

Caveats: ⚠️ Naproxen is a chronic-NSAID with real gastrointestinal bleeding and cardiovascular harm signals in humans — the exact opposite of a longevity bet outside a trial setting. It is not sold, dosed, or recommended here for longevity in any form. If you take NSAIDs long-term, that is a conversation with your GP.

Browse compound data→ compound index (no page yet)

Named a prescription medicine? Decisions on starting, stopping, or combining belong with a qualified clinician.

Thymus / TCR-diversity programs (e.g. Rothblatt-backed thymus regeneration)

What's coming, not buyable

Evidence: Pipeline-level programs (thymus regeneration, T-cell receptor diversity restoration) target a core mechanism of immune ageing. Scientifically serious money is moving here.

Caveats: Not approved, not available, no human outcome data. If a clinic offers to sell you this today, that is exactly the pattern the FDA warned US longevity clinics about in 2025. Watch the space; keep your wallet closed.

Browse compound data→ compound index (no page yet)

Named a prescription medicine? Decisions on starting, stopping, or combining belong with a qualified clinician.

How people actually access these — the subscription economy

Almost nobody buys longevity interventions as one-off purchases anymore. The industry's recurring-revenue pattern — the same one that made GLP-1s blockbusters — is the subscription: monthly telehealth plans, annual clinic memberships, rolling supplement deliveries. Here are the three categories, compared honestly. We have no paid partnerships with any provider and name no clinics as endorsements; this is a map, not a recommendation. See also our prescription pathways guide.

Access routeTypical costBilling modelWhat you getGovernance
UK private telehealth prescribing (weight-management / metabolic clinics)≈ £150–£300 / monthMonthly subscription, usually incl. medicationClinician consult, GLP-1 (or metformin, where appropriate) prescribed for approved indications, reviews and titrationGMC-registered prescribers; CQC-registered services; GPhC pharmacies. Prescription-only, clinician-governed
Longevity membership clinics (Fountain Life-style model, mostly US)≈ $3k–$20k+ / yearAnnual membership subscriptionDiagnostics (whole-body MRI, CIMT, advanced bloods), physician-led protocols, sometimes experimental off-label prescribingPhysician-led but variable; US-centric. Off-label use sits outside MHRA-approved indications — assess carefully
Supplement subscriptions (NMN/NR, taurine, omega-3, ...)≈ £10–£60 / monthMonthly rolling subscriptionProducts delivered on schedule; tier-B/C molecules mostly; no clinician involved by defaultFood-supplement law, not medicines regulation. No medicinal claims permitted; product quality varies — third-party-tested brands only

Why governance is the column that matters: the FDA sent warning letters to US longevity clinics and pharmacies in 2025 for exactly the pattern to avoid — selling unapproved drug products on anti-aging claims. In the UK, prescription-only medicines reach you through clinicians (GMC-registered prescribers, CQC-registered services, GPhC pharmacies) or not at all. Supplements are regulated as food, not medicines — which is precisely why the claims on the label and the contents of the tub deserve your scepticism.

The dataset nobody else is building

Trials tell you what happens on average; the community tells you what happened to people like you. If you take semaglutide, metformin, rapamycin, NMN, taurine, or any of the compounds above — share your outcome and the next person Googling "does this actually work?" gets a real answer instead of marketing copy.

Share an outcomeBrowse compound data

Disclaimer

This page is education and evidence review, not medical advice. Works for Us does not sell medicines of any kind, does not prescribe, and does not diagnose. Prescription-only medicines require a consultation with a qualified clinician who can assess whether they are appropriate for you. Supplements are not medicines and must not be used as substitutes for medical treatment. Speak to your GP, pharmacist, or another qualified healthcare professional before starting, stopping, or combining anything mentioned here. If a provider offers you prescription drugs without clinician involvement, walk away.

Sources